ESGCT, Berlin, Germany
Five abstracts are accepted for one oral and four poster presentations at the 25th meeting of the European Society of Gene and Cell Therapy (ESGCT) concerning both of its lead products.
=> GS010 – Leber’s Hereditary Optic Neuropathy (LHON)
78 week follow-up study results after intravitreal rAAV2/2-ND4 (GS010) injection in patients with vision loss due to G11778A ND4 Leber Hereditary Optic Neuropathy.
- Poster Presentation ID P215
- Wednesday 18th October 2017, 6:30 pm-9:00 pm
Humoral and cellular immune responses to AAV2 and ocular inflammation in patients after intravitreal injection of rAAV2/2-ND4 (GS010), an investigational gene therapy for the treatment of ND4 LHON
- Poster Presentation ID P210
- Thursday 19th October 2017, 6:45 pm-8:15 pm
=> GS030 – Optogenetics in Retinitis Pigmentosa (RP)
Efficacy and Safety of ocular AAV mediated optogenetic therapy for retinitis pigmentosa in rd1 mice and non-human primates support the First-in-Human clinical trial of GS030
- Oral presentation OR07
- Session S1b : Ocular and CNS Gene and Cell Therapy I
- Wednesday 18 October 2017, 08:30 – 10:40 am
Ocular tolerability of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) gene therapy product on blind rd1 mice injected intravitreously and exposed to 595 nm LED light
- Poster Presentation ID P231
- Wednesday 18th October 2017, 6:30 pm-9:00 pm
Toxicity, immunogenicity and biodistribution of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) gene therapy product after bilateral intravitreal administration in non-human primates
- Poster Presentation ID P214
- Thursday 19th October 2017, 6:45 pm-8:15 pm